523 related articles for article (PubMed ID: 36737746)
61. Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy.
Nagai Y; Mukai K; Otsuki M; Kimura T; Kozawa J; Nishizawa H; Maeda N; Matsuoka TA; Iwahashi H; Imagawa A; Shimomura I
Intern Med; 2019 Apr; 58(7):949-953. PubMed ID: 30568127
[TBL] [Abstract][Full Text] [Related]
62. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
63. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
64. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
65. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.
Su YC; Hung JH; Chang KC; Sun CC; Huang YH; Lee CN; Hung MJ; Lai CC; Shao SC; Lai EC
JAMA Netw Open; 2022 Sep; 5(9):e2232584. PubMed ID: 36136333
[TBL] [Abstract][Full Text] [Related]
66. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
Najafi S; Bahrami M; Butler AE; Sahebkar A
Br J Clin Pharmacol; 2022 Aug; 88(8):3627-3637. PubMed ID: 35384008
[TBL] [Abstract][Full Text] [Related]
67. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.
Mosenzon O; Schechter M; Leibowitz G
Adv Chronic Kidney Dis; 2021 Jul; 28(4):347-360. PubMed ID: 34922691
[TBL] [Abstract][Full Text] [Related]
68. Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert SG; Wood EM; Ahir V
Diabetes Metab Syndr; 2023 Jan; 17(1):102696. PubMed ID: 36596264
[TBL] [Abstract][Full Text] [Related]
69. Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.
Pasternak B; Wintzell V; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Svanström H; Ueda P
Diabetes Care; 2020 Jun; 43(6):1326-1335. PubMed ID: 32295809
[TBL] [Abstract][Full Text] [Related]
70. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
71. Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan.
Shao SC; Su YC; Lai EC; Chang KC; Lee CN; Hung MJ; Lai CC; Huang FC; Hung JH
Diabetes Metab; 2022 Jan; 48(1):101318. PubMed ID: 35017100
[TBL] [Abstract][Full Text] [Related]
72. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
73. Utilization of glucagon-like peptide-1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database.
Hirose N; Tsujimoto N; Katayose T; Chin R
Diabetes Obes Metab; 2022 Mar; 24(3):486-498. PubMed ID: 34779098
[TBL] [Abstract][Full Text] [Related]
74. Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.
Li X; Song Y; Guo T; Xiao G; Li Q
Diabetes Metab; 2022 Sep; 48(5):101366. PubMed ID: 35760374
[TBL] [Abstract][Full Text] [Related]
75. Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Wu CT; Chu PH
Diabetes Res Clin Pract; 2021 Oct; 180():109076. PubMed ID: 34599973
[TBL] [Abstract][Full Text] [Related]
76. GLP-1 Treatment Improves Diabetic Retinopathy by Alleviating Autophagy through GLP-1R-ERK1/2-HDAC6 Signaling Pathway.
Cai X; Li J; Wang M; She M; Tang Y; Li J; Li H; Hui H
Int J Med Sci; 2017; 14(12):1203-1212. PubMed ID: 29104476
[No Abstract] [Full Text] [Related]
77. Causal effects of gut microbiota on diabetic retinopathy: A Mendelian randomization study.
Liu K; Zou J; Fan H; Hu H; You Z
Front Immunol; 2022; 13():930318. PubMed ID: 36159877
[TBL] [Abstract][Full Text] [Related]
78. Impact of Genetic Loci Identified in Genome-Wide Association Studies on Diabetic Retinopathy in Chinese Patients With Type 2 Diabetes.
Cheung CY; Hui EY; Lee CH; Kwok KH; Gangwani RA; Li KK; Chan JC; Woo YC; Chow WS; Yuen MM; Wong RL; Fong CH; Xu A; Wong DS; Sham PC; Lam KS
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5518-5524. PubMed ID: 27768789
[TBL] [Abstract][Full Text] [Related]
79. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
[TBL] [Abstract][Full Text] [Related]
80. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
